<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00671619</url>
  </required_header>
  <id_info>
    <org_study_id>ESBA105CRD01</org_study_id>
    <nct_id>NCT00671619</nct_id>
  </id_info>
  <brief_title>Study of ESBA105 Eye Drops in Healthy Subjects</brief_title>
  <official_title>A Phase I, Randomized, Vehicle-Controlled, Double-Blind, Mono-Centric, Single and Repeated Dose, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ESBA105 Eye Drops in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ESBATech AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ESBATech AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:&#xD;
&#xD;
      To evaluate the safety, tolerability and pharmacokinetics of ESBA105 administered topically&#xD;
      to the eye for up to 28 days in healthy volunteers.&#xD;
&#xD;
      To determine the systemic exposure to ESBA105 upon single and repeated-dose topical&#xD;
      application to the eye in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ESBA105 is an anti TNF single chain antibody fragment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability</measure>
    <time_frame>several timepoints</time_frame>
  </primary_outcome>
  <enrollment type="Actual">27</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ESBA105</intervention_name>
    <description>eye drops</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female Caucasian subjects.&#xD;
&#xD;
          -  Written informed consent prior to any study procedures including screening tests for&#xD;
             eligibility.&#xD;
&#xD;
          -  Subjects should be in good health as determined by past medical history, physical&#xD;
             examination, vital signs, electrocardiogram, and laboratory tests at screening.&#xD;
&#xD;
          -  Normal sitting blood pressure and pulse rate, i.e.: BP: 100-160 mm Hg systolic, 50-90&#xD;
             mm Hg diastolic and pulse rate: 45-100 bpm. Blood pressure and pulse will be measured&#xD;
             after 3 minutes resting in a sitting position.&#xD;
&#xD;
          -  Bilateral corrected visual acuity of at least 0.9&#xD;
&#xD;
          -  No need for regular concomitant medication.&#xD;
&#xD;
          -  Ability to communicate well with the investigator and comply with the requirements of&#xD;
             the entire study.&#xD;
&#xD;
          -  Use of qualified contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any evidence of infectious disease as evidenced by medical history, clinical&#xD;
             examination, positive serology results which indicate the presence of hepatitis B and/&#xD;
             or C or HIV infection or positive results of the QuantiFERON TB Gold test based latent&#xD;
             tuberculosis testing.&#xD;
&#xD;
          -  History of serious adverse reactions or hypersensitivity to any drug.&#xD;
&#xD;
          -  Presence or history of any allergy including allergic conjunctivitis requiring acute&#xD;
             or chronic treatment (seasonal allergic rhinitis not associated to conjunctivitis&#xD;
             which requires no treatment may be tolerated).&#xD;
&#xD;
          -  Abnormal physical findings of clinical significance at the screening examination or&#xD;
             baseline which would interfere with the objectives of the study.&#xD;
&#xD;
          -  Existence of any surgical or medical condition which might interfere with the&#xD;
             evaluation of the general drug safety and tolerability including clinically relevant&#xD;
             ophthalmological diseases, impaired renal or hepatic function, diabetes mellitus,&#xD;
             cardiovascular abnormalities, haematological abnormalities, psychiatric diseases,&#xD;
             chronic symptoms of pronounced constipation or diarrhoea or conditions associated with&#xD;
             total or partial obstruction of the urinary tract.&#xD;
&#xD;
          -  Shallow anterior chamber, closed angle glaucoma or any other contraindication to eye&#xD;
             dilation for ophthalmological examination.&#xD;
&#xD;
          -  History or presence of any other clinically relevant (in the opinion of the&#xD;
             Investigator) ocular disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Swiss Pharma Contract</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>April 28, 2008</study_first_submitted>
  <study_first_submitted_qc>May 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2008</study_first_posted>
  <last_update_submitted>August 22, 2008</last_update_submitted>
  <last_update_submitted_qc>August 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Peter Lichtlen, Medical Director</name_title>
    <organization>ESBATech AG</organization>
  </responsible_party>
  <keyword>opthalmology</keyword>
  <keyword>antibody fragment</keyword>
  <keyword>TNF alpha</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

